Randomised phase III trial of adjuvant radiotherapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised low-risk luminal A early breast cancer

在分子特征低风险 Luminal A 早期乳腺癌患者中进行辅助放疗与保乳手术和内分泌治疗后观察的随机 III 期试验

• 批准号: nhmrc : 1099899
• 负责人: A/Pr Nicholas Wilcken
• 金额: $ 282.81万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/randomised-phase-iii-breast-cancer/662476
• 关键词: Randomised; phase; III; trial; adjuvant

Radiotherapy after surgery for early breast cancer decreases recurrence but its benefit varies. Thus, it is important to identify low-risk patients who are unlikely to benefit from radiotherapy, sparing them its toxicity and costs. We propose a randomised study to investigate if patients whose breast cancer is postulated to be low-risk based on PAM50 (a 50-gene test) may safely omit radiotherapy after surgery. If successful, these patients will be able to avoid the risks of over-treatment.

早期乳腺癌术后放射治疗可降低复发率，但其益处各不相同。因此，重要的是要识别不太可能从放射治疗中受益的低风险患者，使他们免于其毒性和成本。我们提出了一项随机研究，以调查基于PAM 50（50个基因测试）被假定为低风险的乳腺癌患者是否可以安全地省略术后放疗。如果成功，这些患者将能够避免过度治疗的风险。